+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Persistent poor long-term prognosis of allogeneic hematopoietic stem cell transplant recipients surviving invasive aspergillosis



Persistent poor long-term prognosis of allogeneic hematopoietic stem cell transplant recipients surviving invasive aspergillosis



Haematologica 97(9): 1357-1363



Voriconazole treatment increases early survival of allogeneic hematopoietic stem cell transplant recipients with invasive aspergillosis. We investigated whether this survival advantage translates into an increased long-term survival. This retrospective study involved all patients with an invasive aspergillosis diagnosis transplanted between September 1997 and December 2008, at the Saint-Louis Hospital, Paris, France. The primary end point was survival up to 36 months. Survival analysis before and after 12 weeks, as well as cumulative incidence analysis in a competing risk framework, were used to assess the effect of voriconazole treatment and other factors on mortality. Among 87 patients, 42 received first-line voriconazole and 45 received another antifungal agent. Median survival time was 2.6 months and survival rate at 36 months was 18%. Overall, there was a significant difference in the survival rates of the two groups. Specifically, there was a dramatic difference in survival rates up to ten months post-aspergillosis diagnosis but no significant difference after this time. Over the first 36 months as a whole, no significant difference in survival rate was observed between the two groups. First-line voriconazole significantly reduced aspergillosis-attributable mortality. However, first-line voriconazole patients experienced a significantly higher probability of death from a non-aspergillosis-attributable cause. Although the prognosis for invasive aspergillosis after stem cell transplantation has dramatically improved with the use of voriconazole, this major advance in care does not translate into increased long-term survival for these severely immunocompromised patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036566010

Download citation: RISBibTeXText

PMID: 22371177

DOI: 10.3324/haematol.2011.058255


Related references

The Serum Galactomannan Index Predicts Mortality in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Probable Pulmonary Invasive Aspergillosis. Biology of Blood and Marrow Transplantation 19(2): S288-S289, 2013

Effects of surgical resection of pulmonary lesions to the relapse of pulmonary aspergillosis in allogeneic hematopoietic stem cell transplant recipients with invasive pulmonary aspergillosis. Zhonghua Nei Ke Za Zhi 55(1): 31-35, 2016

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with a History of Prior Invasive Aspergillosis Outcomes and Risks for Post-Transplant Invasive Aspergillosis. Blood 100(11): Abstract No. 2463, 2002

Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients. Transplant Infectious Disease 10(3): 156-161, 2008

Long-term follow up of invasive aspergillosis in allogeneic stem cell transplantation recipients and leukemia patients: Differences in risk factors and outcomes. Current Research in Translational Medicine 65(2): 77-81, 2017

Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA). Bone Marrow Transplantation 36(10): 873-877, 2005

Invasive aspergillosis in hematopoietic stem cell transplant recipients: a retrospective analysis. Brazilian Journal of Infectious Diseases 12(5): 385-389, 2008

Invasive aspergillosis in hematopoietic stem cell transplant recipients a retrospective analysis. Brazilian Journal Of Infectious Diseases: 5, 385-389, 2008

Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100(13): 4358-4366, 2002

Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clinical Infectious Diseases 34(7): 939-943, 2002

Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. International Journal of Antimicrobial Agents 30(6): 551-554, 2007

The value of serum galactomannan detection for diagnosis of invasive aspergillosis in hematopoietic stem cell transplant recipients. Zhonghua Xue Ye Xue Za Zhi 28(2): 83-86, 2007

Is combination antifungal therapy for invasive aspergillosis a necessity in hematopoietic stem-cell transplant recipients?. Current Opinion in Infectious Diseases 19(4): 371-379, 2006

Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. Journal of Infectious Diseases 186(9): 1297-1306, 2002

Low incidence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis. Transplant Infectious Disease 14(1): 24-32, 2012